FPI 2068
Alternative Names: [225Ac]-FPI-2068; actinium-225 FPI-2068; FPI-2068Latest Information Update: 25 Jul 2024
At a glance
- Originator AstraZeneca; Fusion Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Jul 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Recurrent) in USA (IV) (NCT06147037)
- 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
- 12 Oct 2023 Pharmacodynamics data from a preclinical study in Cancer released by Fusion Pharmaceuticals